

Revised HOME-CoV - Study on the implementation of the revised HOME-CoV score to guide the choice of hospitalisation or outpatient management of patients with confirmed or probable SARS-CoV-2 infection admitted to an emergency department.

Head :Douillet Delphine

Last update : 05/05/2021 | Version : 1 | ID : 73909

| General | |
|--|--|
| Identification | |
| Detailed name | Study on the implementation of the revised HOME-CoV score to guide the choice of hospitalisation or outpatient management of patients with confirmed or probable SARS-CoV-2 infection admitted to an emergency department. |
| Sign or acronym | Revised HOME-CoV |
| CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | 2020-A03067-32 |
| General Aspects | |
| Medical area | Emergency medicine |
| Study in connection with Covid-19 | Yes |
| Health determinants | Healthcare system and access to health care services |
| Keywords | COVID-19; Hospitalization; Outpatient; Rule validation; Expert consensus; Rule-based decision-making; Clinical support decision tool. |
| Scientific investigator(s) (Contact) | |
| Name of the director | Douillet |
| Surname | Delphine |
| Address | Departement de Médecine d'Urgence 4 rue Larrey CHU ANGERS |

Email Delphine.Douillet@chu-angers.fr

Collaborations

Funding

Funding status Public

Details Angers University Hospital

Governance of the database

Sponsor(s) or organisation(s) responsible Angers University Hospital

Organisation status

Additional contact

Main features

Type of database

Type of database Study databases

Study databases (details) Cohort study

Database recruitment is carried out by an intermediary A selection of health institutions and services

Database recruitment is made on the basis of: Another treatment or procedure

Database recruitment is carried out as part of an interventional study Yes

Details Performed at group level (clusters)

Database objective

Main objective

The primary objective is to demonstrate the reliability and safety of outpatient management among patients highly suspected or confirmed as infected with COVID-19, attending an emergency department and with a revised HOME-CoV score less than 2 (negative rule).

The secondary objectives are as follows:

- Evaluate the rate of patients having required hospitalisation within 7 days following inclusion according to the revised positive or negative HOME-

CoV rule.

- ii. Evaluate the rate of patients having required hospitalisation and initiation of oxygen therapy within 7 days following inclusion according to the revised positive or negative HOME-CoV rule.
- iii. Evaluate the rate of patients having required intubation within 7 days following inclusion according to the revised positive or negative HOME-CoV rule.
- iv. Evaluate the rate of all-cause deaths within 7 days following inclusion according to the revised positive or negative HOME-CoV rule.
- v. Evaluate the performance of the revised HOME-CoV score in predicting a negative outcome in the patient subgroup with SARS-CoV-2 infection confirmed by RT-PCR to rule out the risk of a negative outcome when assessed as low risk.
- vi. Compare the performance of the revised HOME-CoV score with that of other existing scores.

| | |
|------------------------------|---|
| Inclusion criteria | Adult patient (> 18 years), <ul style="list-style-type: none">- Attending one of the emergency departments taking part in the study due to COVID-19 infection confirmed by SARS-CoV-2 positive RT-PCR, or considered highly probable by the physician managing the patient,- Not requiring management in a continuous care or intensive care unit, and subject to a decision to limit active treatment,- Having given their formal consent to take part in the study,- Registered with or a beneficiary of a social security scheme. |
| Population type | |
| Age | Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more) |
| Population covered | Sick population |
| Pathology | B33 - Other viral diseases, not elsewhere classified |
| Gender | Male Woman |
| Geography area | International |
| Detail of the geography area | France Belgium |

Data collection

Dates

Size of the database

Size of the database (number of individuals) [1000-10 000[individuals

Details of the number of individuals 1,300 patients

Data

Database activity Current data collection

Type of data collected
Clinical data
Declarative data
Paraclinical data
Biological data
Administrative data

Clinical data (detail) Direct physical measures
Medical registration

Declarative data (detail) Face to face interview

Procedures

Followed pathology

Promotion and access

Promotion

Access